Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $47
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $47.
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $50 to $47.